Leading global law firm Baker McKenzie has advised Numab Therapeutics, a clinical stage biopharmaceutical company developing next-generation multispecific antibody-based immunotherapies for cancer and inflammation, on the successful closing of a CHF 100 million (approximately USD 110 million) Series C financing.
The financing was co-led by new investors Novo Ventures, the ventures arm of Novo Holdings, and HBM Partners, with participation from additional new investors Forbion via its Forbion Growth Opportunities Fund, Cormorant Asset Management, BVF Partners L.P., RTW Investments L.P., funds and accounts under the management of BlackRock, Octagon Capital Advisors, and existing investors.
Proceeds will support acceleration and expansion of the clinical development of Numab’s lead program NM21-1480 into multiple cancer indications, and the advancement of the company’s pipeline of multi-specific antibodies in oncology and inflammation, into clinical trials.
Baker McKenzie advised Numab Therapeutics on all legal aspects of the transaction with a team led by Partners Martin Frey and Berthold Hummel, and Senior Associates, Ramon Tissafi, Matthias Trautmann and Julia Schieber.
Baker McKenzie's Corporate / M&A and life science team regularly advises big pharma, financial investors and early stage biotech companies on domestic and international healthcare transactions. Most recently, Baker McKenzie advised CatalYm on a EUR 50 million Series B financing led by Vesalius Capital to advance its immunoncology development, Casdin Capital on a USD 50 million extension of the Series B Equity Financing in DNA Script, Chr. Hansen Holding on the acquisition of Jennewein Biotechnologie, BioMedPartners on its Series A Equity Financing of € 10.7 million in Tubulis, CureVac on its strategic mRNA technology collaboration with GSK, LSP Life Science Partners on a USD 38.5 Million Series B Financing in DNA Script, listed 4SC AG on a capital increase and international private placement, Galapagos on its 10 year global research and development collaboration with Gilead, MODAG on a € 12 million Series A Financing, Hitachi Chemical Company, Tokyo on the take-over of German apceth Biopharma, Forbion as lead investor on a € 17 million Series C Equity Financing of Omeicos Therapeutics as well as on a USD 54 million Series A Equity Financing of Gotham Therapeutics Corporation, Mundipharma on the sale of its Limburg production, CureVac AG on a collaboration with Eli Lilly and Hillhouse Capital as co-investor in the € 50 million Series C financing of Hookipa Biotech.